

**Polasky, Alexandra**

---

**From:** McNeill, Lorrie  
**Sent:** Thursday, November 9, 2017 10:38 AM  
**To:** Anderson, Steven; Gruber, Marion; Hess, Maureen  
**Cc:** Bartell, Diane; Gardner, Walter; Bell, Maureen; Raine, Kristine  
**Subject:** Letter from ICAN re: vaccine safety  
**Attachments:** 2017-5555(b) - DR - Bigtree, Del - HHS Vaccine Safety Responsibilities and Notice Pursuant 42 USC 300aa-31.pdf

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie



NOV 07 2017

VIA FEDEX

November 6, 2017

U.S. Department of Health & Human Services  
HHS Office of the Secretary  
Eric D. Hargan  
Acting Secretary of Health & Human Services  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Re: *Correspondence Email Address*

Dear Secretary Hargan:

As a follow-up to our letter, dated October 12, 2017 (copy enclosed), any response to same should be sent via electronic mail to [del@icandecide.com](mailto:del@icandecide.com) and [cat@icandecide.com](mailto:cat@icandecide.com)

Very truly yours,

A handwritten signature in black ink, appearing to read "Del Bigtree". The signature is stylized and cursive.

Del Bigtree

Enclosure: *Copy of letter from  
Del Bigtree to Eric D. Hargan  
dated October 12, 2017*



**VIA FEDEX**

October 12, 2017

U.S. Department of Health & Human Services  
HHS Office of the Secretary  
Don Wright, M.D., M.P.H.  
Acting Secretary of Health & Human Services  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

*Re: HHS Vaccine Safety Responsibilities and Notice Pursuant to 42 U.S.C. § 300aa-31*

Dear Secretary Wright:

Informed Consent Action Network hereby provides notice per 42 U.S.C. § 300aa-31(b).

Americans, including the over 55 organizations listed below, whose members exceed 5 million Americans, are concerned about vaccine safety. The National Childhood Vaccine Injury Act of 1986 (the 1986 Act) made nearly every aspect of vaccine safety the exclusive responsibility of the Department of Health & Human Services (HHS). As the Secretary of HHS (the Secretary), this means you shoulder virtually all responsibility for assuring the safety of vaccines administered to America's 78 million children.

This notice respectfully requests confirmation that certain obligations regarding vaccine safety required under the 1986 Act have been fulfilled or will forthwith be fulfilled. These specific requests are numbered sequentially in this notice. We would welcome the opportunity to meet and discuss reasonable means for complying with these requests. If that is not possible, the 1986 Act authorizes "a civil action ... against the Secretary where there is alleged a failure of the Secretary to perform any act or duty" under the 1986 Act.

**I. Background**

The 1986 Act granted economic immunity to pharmaceutical companies for injuries caused by their vaccines. (42 U.S.C. § 300aa-11.) The 1986 Act thereby eliminated the market force which drives safety for all other products – actual and potential product liability. Recognizing the unprecedented elimination of this market force, the 1986 Act makes HHS directly responsible for virtually every aspect of vaccine safety. (42 U.S.C. §§ 300aa-2, 300aa-27.)

When the CDC recommends a pediatric vaccine for universal use, it creates for that vaccine's maker a liability free market of 78 million children typically required by law to receive the vaccine. The number of required vaccines has grown rapidly since 1986. In 1983, the CDC recommended that babies under one receive two vaccines: DTP and Polio.<sup>1</sup> As of 2017, the CDC recommends that babies under one receive multiple doses of ten vaccines: DTaP, Polio, Hep B, Rotavirus, Hib, Pneumococcal, Influenza, MMR, Varicella, and Hep A.<sup>2</sup> In total, the current CDC childhood vaccine schedule includes 56 injections of 73 doses of 30 different vaccines.

## II. Deficiencies in the Pre-Licensure Safety Review of Pediatric Vaccines

All drugs licensed by the FDA undergo long-term double-blind pre-licensure clinical trials during which the rate of adverse reactions in the group receiving the drug under review is compared to the rate of adverse reactions in a group receiving an inert placebo, such as a sugar pill or saline injection. For example: Enbrel's pre-licensure trials followed subjects up to 80 months and controls received a saline injection.<sup>3</sup> Lipitor's pre-licensure trials lasted a median of 4.8 years and controls received a sugar pill.<sup>4</sup> Botox's pre-licensure trials lasted a median of 51 weeks and controls received a saline injection.<sup>5</sup> And even with these long-term studies, drugs are still often recalled.

In contrast, vaccines are *not* required to undergo long-term double-blind inert-placebo controlled trials to assess safety. In fact, not a single one of the clinical trials for vaccines given to babies and toddlers had a control group receiving an inert placebo. Further, most pediatric vaccines currently on the market have been approved based on studies with inadequate follow-up periods of only a few days or weeks.

For example, of the two Hepatitis B vaccines licensed by the FDA for injection into one-day-old babies, Merck's was licensed after trials that solicited adverse reactions for *only five days* after vaccination and GlaxoSmithKline's was licensed after trials that solicited adverse reactions for *only four days* after vaccination.<sup>6</sup> Similarly, the Hib vaccines sold by these same companies were licensed based on trials which solicited adverse reactions for three and four days, respectively, after vaccination.<sup>7</sup> The only stand-alone polio vaccine was licensed after a mere 48-hour follow-up period.<sup>8</sup>

<sup>1</sup> <https://www.cdc.gov/vaccines/schedules/imz/schedule1983a.htm>

<sup>2</sup> <https://www.cdc.gov/vaccines/schedules/hp/imz/child-adolescent.html>

<sup>3</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/103793s501/1b1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103793s501/1b1.pdf)

<sup>4</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/030702/0456/1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/030702/0456/1.pdf)

<sup>5</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/032000s520/1a1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/032000s520/1a1.pdf)

<sup>6</sup> <https://www.fda.gov/downloads/Biologics/Blood/Vaccines/Vaccines/ApprovedProducts/UCM118114.pdf>

<sup>7</sup> <https://www.fda.gov/downloads/Biologics/Blood/Vaccines/Vaccines/ApprovedProducts/UCM224503.pdf>

<sup>8</sup> <https://www.fda.gov/downloads/Biologics/Blood/Vaccines/Vaccines/ApprovedProducts/UCM253652.pdf>

<sup>9</sup> <https://www.fda.gov/downloads/Biologics/Blood/Vaccines/Vaccines/ApprovedProducts/UCM179630.pdf>

<sup>10</sup> <https://www.fda.gov/downloads/Biologics/Blood/Vaccines/Vaccines/ApprovedProducts/UCM13479.pdf>

Moreover, these trials either had no control group or a control group which received other vaccines as a “placebo.”<sup>9</sup> This means each new vaccine need only be roughly as safe as one (or in some cases numerous) previously licensed vaccines. Such flawed and unscientific study designs cannot establish the actual safety profile of any vaccine. The real adverse event rate for a vaccine can only be determined by comparing subjects receiving the vaccine with those receiving an inert placebo. Yet, this basic study design, required for every drug, is not required before or after licensing a vaccine.

The 1986 Act expressly requires that you, as the Secretary, “shall make or assure improvements in ... the licensing ... and research on vaccines, in order to reduce the risks of adverse reactions to vaccines.” (42 U.S.C. § 300aa-27(a)(2).) Given this statutory obligation:

- (1) Please explain how HHS justifies licensing any pediatric vaccine without first conducting a long-term clinical trial in which the rate of adverse reactions is compared between the subject group and a control group receiving an inert placebo?
- (2) Please list and provide the safety data relied upon when recommending babies receive the Hepatitis B vaccine on the first day of life?

### III. Post-Licensure Surveillance of Vaccine Adverse Events

The lack of pre-licensure safety data leaves the assessment of vaccine safety to the post-licensing period when they are being administered to children in the “real world.” To capture vaccine adverse events in the real world, the 1986 Act established the Vaccine Adverse Events Reporting System (VAERS) operated by HHS. (42 U.S.C. § 300aa-25.)

In 2016, VAERS received 59,117 reports of adverse vaccine events, including 432 deaths, 1,091 permanent disabilities, 4,132 hospitalizations, and 10,284 emergency room visits.<sup>10</sup>

However, only a tiny fraction of adverse vaccine events are reported to VAERS. An HHS-funded study by Harvard Medical School tracked reporting to VAERS over a three-year period at Harvard Pilgrim Health Care involving 715,000 patients and found that “fewer than 1% of vaccine adverse events are reported.”<sup>11</sup> A U.S. House Report similarly stated: “Former FDA Commissioner David A. Kessler has estimated that VAERS reports currently represent only a fraction of the serious adverse events.”<sup>12</sup>

---

<sup>9</sup> Ibid.

<sup>10</sup> <https://vaers.hhs.gov/vaers.html>

<sup>11</sup> <https://www.fda.gov/oc/ohrt/files/docs/publicness/18shd17043-lazans-final-report-2011.pdf>

<sup>12</sup> <https://www.congress.gov/116/records/116/hrpt/977/CRRPT-116/hrpt977.pdf>

Assuming VAERS captures a full 1 percent of adverse events – which is more than is estimated – the VAERS data above from 2016 may reflect that in that year alone there were 5,911,700 adverse vaccine events, including 43,200 deaths, 109,100 permanent disabilities, 413,200 hospitalizations, and 1,028,400 emergency room visits.

Of course, these figures are merely estimates. It would be far better if adverse events reports were automatically created and submitted to VAERS to avoid the issue of underreporting. Automated reporting would provide invaluable information that could clarify which vaccines might cause which harms and to whom, potentially avoiding these injuries and deaths.

The idea of automating adverse reaction reporting to VAERS is not new or even difficult to achieve.<sup>13</sup> An agency within HHS, the Agency for Healthcare Research and Quality, sought to do exactly that in 2007 when it provided an approximately \$1 million grant to automate VAERS reporting at Harvard Pilgrim Health Care.<sup>14</sup> The result was the successful automation of adverse event reports at Harvard Pilgrim:

*Preliminary data were collected from June 2006 through October 2009 on 715,000 patients, and 1.4 million doses (of 45 different vaccines) were given to 376,452 individuals. Of these doses, 35,570 possible reactions ... were identified.<sup>15</sup>*

These results should have been concerning to HHS since they show that over only a three-year period, there were 35,570 reportable reactions in just 376,452 vaccine recipients.

After automating adverse events reports at Harvard Pilgrim, the developers of this system asked the CDC to take the final step of linking VAERS with the Harvard Pilgrim system so that these reports could be automatically transmitted into VAERS. Instead, the CDC refused to cooperate. As the Harvard grant recipients explained:

*Unfortunately, there was never an opportunity to perform system performance assessments because the necessary CDC contacts were no longer available and the CDC consultants responsible for receiving data were no longer responsive to our multiple requests to proceed with testing and evaluation.<sup>16</sup>*

After three years and spending \$1 million of taxpayers' money, the CDC refused to even communicate with the HHS' Harvard Medical School grant recipients. Given HHS's statutory mandate to assure safer vaccines, it should have rushed forward with automating VAERS reporting – not ignored the requests by the HHS's Harvard grant recipients.

<sup>13</sup> <https://healthit.ahrq.gov/ahrq-funded-projects/electronic-reporting-public-health-vaccine-adverse-event-reporting-system>

<sup>14</sup> <https://healthit.ahrq.gov/sites/default/files/docs/publication/15hs012015-juzarus-final-report-2011.pdf>

<sup>15</sup> *Ibid.*

<sup>16</sup> *Ibid.*

While HHS strongly supports automating public health surveillance systems, when it comes to vaccine safety, the CDC has only supported projects that would limit VAERS to passive surveillance.<sup>17</sup> Automation would improve safety and address many of the long-standing issues and limitations raised by CDC regarding VAERS.<sup>18</sup> Capturing “fewer than 1% of vaccine adverse events” thirty years after the passage of the 1986 Act is unacceptable – and potentially deadly.

The 1986 Act expressly provides that you, as the Secretary, “shall make or assure improvements in ... adverse reaction reporting ... in order to reduce the risks of adverse reactions to vaccines.” (42 U.S.C. § 300aa-27(a)(2).) Given this statutory obligation:

**(3) Please explain why HHS failed to cooperate with Harvard to automate VAERS reporting? And detail any steps that HHS has taken since toward automating VAERS reporting?**

**(4) Please explain any specific steps taken by HHS to improve adverse reaction reporting to VAERS?**

#### **IV. Identifying What Injuries Are Caused by Vaccines**

The first step in assuring safer vaccines is to identify what harms they cause. This would normally be accomplished pre-licensure by long-term, inert-placebo controlled trials – but these are never performed for vaccines. As for post-licensure monitoring, HHS has refused to improve VAERS as discussed above. Hence, assessing which vaccines cause which injuries is mainly left to post-licensure studies. HHS, unfortunately, has neglected to perform these studies.

In 1991, the Institute of Medicine (IOM) examined 22 commonly reported serious injuries following the DTP vaccine.<sup>19</sup> The IOM concluded the scientific literature supported a causal relationship between the DTP vaccine and 6 of these injuries: acute encephalopathy, chronic arthritis, acute arthritis, shock and unusual shock-like state, anaphylaxis, and protracted inconsolable crying.<sup>20</sup> The IOM, however, found the scientific literature was insufficient to conclude whether or not the DTP vaccine can cause 12 other serious injuries:

*Aseptic meningitis; Chronic neurologic damage; Learning disabilities and attention-deficit disorder; Hemolytic anemia; Juvenile diabetes; Guillain-Barre syndrome; Erythema multiforme; Autism; Peripheral mononeuropathy; Radiculoneuritis and other neuropathies; Thrombocytopenia; Thrombocytopenic purpura<sup>21</sup>*

<sup>17</sup> [http://www.alpmedline.org/article/50749-3797\(12\)33249-3.pdf](http://www.alpmedline.org/article/50749-3797(12)33249-3.pdf) <https://www.ncbi.nlm.nih.gov/pubmed/26209830> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632204/>

<sup>18</sup> *Ibid.*

<sup>19</sup> <https://www.iom.edu/read/1015/chapter/357>

<sup>20</sup> *Ibid.*

<sup>21</sup> *Ibid.*

The IOM lamented that it “encountered many gaps and limitations in knowledge bearing directly and indirectly on the safety of vaccines” and on the poor design of the few existing studies.<sup>22</sup> It therefore cautioned that: “If research capacity and accomplishment in this field are not improved, future reviews of vaccine safety will be similarly handicapped.”<sup>23</sup>

In 1994, the IOM issued another report which examined the scientific literature for evidence that could either prove or disprove a causal link between 54 commonly reported serious injuries and vaccination for diphtheria, tetanus, measles, mumps, polio, hepatitis B, and Hib.<sup>24</sup> The IOM located sufficient science to support a causal connection between these vaccines and 12 injuries, including death, anaphylaxis, thrombocytopenia, and Guillain-Barre syndrome.<sup>25</sup> The IOM, however, found the scientific literature was insufficient to conclude whether or not these vaccines caused 38 other commonly reported serious injuries, including:

*Demyelinating diseases of the central nervous system, Sterility, Arthritis, Neuropathy, Residual seizure disorder, Transverse myelitis, Sensorineural deafness, Optic neuritis, Aseptic meningitis, Insulin-dependent diabetes mellitus, SIDS*<sup>26</sup>

As in 1991, this IOM Report again stated, “The lack of adequate data regarding many of the adverse events under study was of major concern to the committee. Presentations at public meetings indicated that many parents and physicians share this concern.”<sup>27</sup>

In 2011, more than fifteen years after the IOM Reports in 1991 and 1994, HHS paid the IOM to conduct another assessment regarding vaccine safety.<sup>28</sup> This third IOM Report reviewed the available science with regard to the 158 most common vaccine injuries claimed to have occurred from vaccination for varicella, hepatitis B, tetanus, measles, mumps, and rubella.<sup>29</sup> The IOM located science which “convincingly supports a causal relationship” with 14 of these injuries, including pneumonia, meningitis, hepatitis, MIBE, febrile seizures, and anaphylaxis.<sup>30</sup> The review found sufficient evidence to support “acceptance of a causal relationship” with 4 additional serious injuries.<sup>31</sup>

The IOM, however, found the scientific literature was insufficient to conclude whether or not those vaccines caused 135 other serious injuries commonly reported after their administration, including:

---

<sup>22</sup> <https://www.nap.edu/read/1815/chapter/28>

<sup>23</sup> <https://www.nap.edu/read/1815/chapter/9>

<sup>24</sup> <https://www.nap.edu/read/2138/chapter/213>

<sup>25</sup> <https://www.nap.edu/read/2138/chapter/213>

<sup>26</sup> *Ibid.*

<sup>27</sup> <https://www.nap.edu/read/2138/chapter/11>

<sup>28</sup> <https://www.nap.edu/read/13164/chapter/22>

<sup>29</sup> *Ibid.*

<sup>30</sup> <https://www.nap.edu/read/13164/chapter/25>

<sup>31</sup> *Ibid.*

*Encephalitis, Encephalopathy, Infantile Spasms, Afebrile Seizures, Seizures, Cerebellar Ataxia, Acute Disseminated Encephalomyelitis, Transverse Myelitis, Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis, Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Brachial Neuritis, Amyotrophic Lateral Sclerosis, Small Fiber Neuropathy, Chronic Urticaria, Erythema Nodosum, Systemic Lupus Erythematosus, Polyarteritis Nodosa, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Arthralgia, Autoimmune Hepatitis, Stroke, Chronic Headache, Fibromyalgia, Sudden Infant Death Syndrome, Hearing Loss, Thrombocytopenia, Immune Thrombocytopenic Purpura*<sup>32</sup>

Thus, out of the 158 most common serious injuries reported to have been caused by the vaccines under review, the evidence supported a causal relationship for 18 of them, rejected a causal relationship for 5 of them, but for the remaining 135 vaccine-injury pairs, over 86 percent of those reviewed, the IOM found that the science simply had not been performed.<sup>33</sup>

The 1986 Act expressly provides that you, as the Secretary, “shall promote the development of childhood vaccines that result in fewer and less adverse reactions” and “shall make or assure improvements in ... the ... labeling, warning, ... and research on vaccines, in order to reduce the risks of adverse reactions to vaccines.” (42 U.S.C. § 300aa-27(a)(2).) The first step in reducing adverse reactions is identifying what adverse reactions are caused by vaccine. Given this statutory obligation:

- (5) For each of the 38 vaccine-injury pairs reviewed in the 1994 IOM Report which the IOM found lacked studies to determine causation, please identify the studies undertaken by the HHS to determine whether each injury is caused by vaccination?
- (6) For each of the 135 vaccine-injury pairs reviewed in the 2011 IOM Report which the IOM found lacked studies to determine causation, please identify the studies undertaken by the HHS to determine whether each injury is caused by vaccination?

Further to your duties to identify what injuries are caused by vaccines, the 1986 Act also expressly requires you to “make or assure improvements in ... the ... recall of reactogenic lots or batches, of vaccines ... in order to reduce the risks of adverse reactions to vaccines” and thus each “health care provider who administers a vaccine ... shall record ... in such person’s permanent

---

<sup>32</sup> Ibid.

<sup>33</sup> Ibid.

medical record ... the vaccine manufacturer and lot number." (42 U.S.C. §§ 300aa-25(a), 300aa-27(a)(2).) Since health care providers often fail to record this information:

(7) Please explain what HHS has done to assure that health care providers record the manufacturer and lot number for each vaccine they administer?

#### V. Identifying Which Children are Susceptible to Vaccine Injury

The IOM has consistently acknowledged there is individual susceptibility to serious vaccine injuries. The IOM has also acknowledged that research on such susceptibility must be done on an individual basis, considering a child's personal genome, behaviors, microbiome, intercurrent illness, and present and past environmental exposure. HHS, unfortunately, has not conducted this research.

In 1994, the IOM, building on concerns raised in its 1991 report, stated: "The committee was able to identify little information pertaining to why some individuals react adversely to vaccines when most do not."<sup>34</sup> The IOM urged that "research should be encouraged to elucidate the factors that put certain people at risk."<sup>35</sup>

Yet, seventeen years later, in 2011, the IOM acknowledged this research had still not been done:

*Both epidemiologic and mechanistic research suggest that most individuals who experience an adverse reaction to vaccines have a preexisting susceptibility. These predispositions can exist for a number of reasons—genetic variants (in human or microbiome DNA), environmental exposures, behaviors, intervening illness, or developmental stage, to name just a few—all of which can interact...*

*Some of these adverse reactions are specific to the particular vaccine, while others may not be. Some of these predispositions may be detectable prior to the administration of vaccine... much work remains to be done to elucidate and to develop strategies to document the immunologic mechanisms that lead to adverse effects in individual patients.<sup>36</sup>*

In 2013, HHS commissioned the IOM to review the safety of the entire vaccine schedule.<sup>37</sup> The IOM again explained that while "most children who experience an adverse reaction to immunization have preexisting susceptibility," the IOM:

---

<sup>34</sup> <https://www.iom.edu/record/2128/chapter/127107>. See also <https://www.iom.edu/record/1615/chapter/9>

<sup>35</sup> *Ibid.*

<sup>36</sup> <https://www.iom.edu/record/13164/chapter/5982>

<sup>37</sup> <https://www.iom.edu/record/13283/chapter/1>

*found that evidence assessing outcomes in sub populations of children who may be potentially susceptible to adverse reactions to vaccines (such as children with a family history of autoimmune disease or allergies or children born prematurely) was limited and is characterized by uncertainty about the definition of populations of interest and definitions of exposures and outcomes.<sup>38</sup>*

HHS had failed to even define the terminology for the study of susceptible subpopulations and hence IOM admonished HHS to “develop a framework that clarifies and standardizes definitions of ... populations that are potentially susceptible to adverse events.”<sup>39</sup>

The IOM correctly points out in 2011 that given the “widespread use of vaccines” and “state mandates requiring vaccination of children ... it is essential that safety concerns receive assiduous attention.”<sup>40</sup> This is the same call for diligent attention that the IOM made in 1991 and 1994. Unfortunately, all of these calls for action have gone unheeded. The critical scientific inquiry to identify individuals susceptible to serious vaccine injury has never been conducted.

The 1986 Act expressly provides that you, as the Secretary, “shall promote the development of childhood vaccines that result in fewer and less adverse reactions” and “shall make or assure improvements in ... the ... labeling, warning, ... and research on vaccines, in order to reduce the risks of adverse reactions to vaccines.” (42 U.S.C. § 300aa-27(a)(2).) Given this statutory obligation:

- (8) Please advise when HHS intends to begin conducting research to identify which children are susceptible to serious vaccine injury? If HHS believes it has commenced this research, please detail its activities regarding same?**

#### **VI. Removing Claim “Vaccines Do Not Cause Autism” from the CDC Website**

HHS, unfortunately, has treated vaccine safety as a public relations issue rather than a public health imperative. For example, the CDC claims on its website that “Vaccines Do Not Cause Autism” even though this broad claim is plainly not supported by the scientific literature.<sup>41</sup>

Indeed, as part of the IOM’s 2011 review of vaccine safety, it was asked by HHS whether there is a causal relationship between autism and the DTaP vaccine administered to children at two, four, six, and fifteen months of age.<sup>42</sup> The IOM could not locate a single study supporting

<sup>38</sup> <https://www.nap.edu/read/13164/chapter/9#138>

<sup>39</sup> *Ibid.*

<sup>40</sup> <https://www.nap.edu/read/13164/chapter/1#28>

<sup>41</sup> <https://www.cdc.gov/vaccinesafety/concerns/autism.html>

<sup>42</sup> <https://www.nap.edu/read/13164/chapter/7#7>



*there's still a lot of shame with that. ... I am completely ashamed of what I did.<sup>51</sup>*

Hence, as for the only vaccine, MMR, actually studied by the CDC with regard to autism, it appears the CDC may have concealed an association between that vaccine and autism.<sup>52</sup>

When the former Director of the National Institute of Health, Dr. Bernadine Healy, was asked about whether public health authorities are correct to claim that vaccines do not cause autism, she answered: "You can't say that."<sup>53</sup> When asked again, Dr. Healy explained: "The more you delve into it – if you look at the basic science – if you look at the research that's been done, in animals – if you also look at some of these individual cases – and, if you look at the evidence that there is no link - what I come away with is: *The question has not been answered.*"<sup>54</sup>

Former NIH Director Dr. Healy goes on to explain:

*This is the time when we do have the opportunity to understand whether or not there are susceptible children, perhaps genetically, perhaps they have a metabolic issue, mitochondrial disorder, immunological issue, that makes them more susceptible to vaccines plural, or to one particular vaccine, or to a component of vaccine... I haven't seen major studies that focus on - three hundred kids, who got autistic symptoms within a period of a few weeks of a vaccine. I think that the public health officials have been too quick to dismiss the hypothesis as irrational, without sufficient studies of causation. ...*

*The reason why they didn't want to look for those susceptibility groups was because they're afraid if they found them – however big or small they were – that that would scare the public away. First of all, I think the public's smarter than that; the public values vaccines. But, more importantly, I don't think you should ever turn your back on any scientific hypothesis because you're afraid of what it might show!<sup>55</sup>*

The CDC has also failed to address the science supporting a link between vaccines and autism.<sup>56</sup> For example, the CDC has not addressed a study which found a 300% increased rate of autism among newborns receiving the hepatitis B vaccine at birth compared to those that did not.<sup>57</sup> Nor a recent and first ever vaccinated vs. unvaccinated pilot study which found vaccinated

---

<sup>51</sup> Ibid.

<sup>52</sup> Studies of MMR and autism are also erroneous because of healthy user bias, which has been emphasized as a serious source of error in epidemiological vaccine safety studies by CDC scientists: <https://doi.org/10.1093/oxfordjournals.aje.a116472>

<sup>53</sup> <http://www.cbsnews.com/news/the-open-question-on-vaccines-and-autism/>

<sup>54</sup> Ibid.

<sup>55</sup> Ibid.

<sup>56</sup> <https://www.cdc.gov/vaccinesafety/concerns/autism.html>

<sup>57</sup> [http://www.cdc.gov/od/oc/press/documents/2010a11.htm#item/Gallagher\\_Guestman\\_HepB\\_2010.pdf](http://www.cdc.gov/od/oc/press/documents/2010a11.htm#item/Gallagher_Guestman_HepB_2010.pdf)

children had a 420% increased rate of autism and that vaccinated preterm babies had an even higher rate of autism.<sup>58</sup> There is also a persuasive body of science supporting a clear connection between aluminum adjuvants in vaccines and autism which the CDC, despite numerous requests, has failed to directly or substantively address.<sup>59</sup> Letters from three aluminum adjuvant experts on this point are attached as Appendix C.

The critical need for HHS to properly engage in vaccine safety science regarding autism is made even more vital by the fact that vaccine makers are immune from liability for vaccine injury and vaccines are not safety-tested prior to licensure to assess whether they cause autism. Without proper long-term trials comparing those receiving the vaccine to an inert-placebo group, it is impossible to know prior to licensure whether these products cause autism. There are also no follow-up studies which compare vaccinated with unvaccinated individuals and hence no supportable basis to claim that vaccines do not cause any cases of autism. For the CDC to make this claim, it must demonstrate that a child receiving the entire vaccine schedule is at no greater risk of becoming autistic than a child that is unvaccinated. No such study has ever been done. The IOM Report referenced above has confirmed that the CDC cannot make this claim even for children receiving only the DTaP vaccine, let alone the entire vaccine schedule.

The 1986 Act expressly provides that you, as the Secretary, are to “develop and disseminate vaccine information materials for distribution by health care providers to the legal representatives of any child or to any other individual receiving a vaccine set forth in the Vaccine Injury Table.” (42 U.S.C. § 300aa-26(a).) This section further provides that:

The information in such materials shall be based on available data and information ... and shall include ... (1) a concise description of the benefits of the vaccine, (2) a concise description of the risks associated with the vaccine, (3) a statement of the availability of the National Vaccine Injury Compensation Program, and (4) such other relevant information as may be determined by the Secretary.

(42 U.S.C. § 300aa-26(c).) The VIS produced for every vaccine, including for DTaP, provides that other relevant information regarding the vaccine is available at the CDC website, [www.cdc.gov](http://www.cdc.gov).<sup>60</sup> The CDC website in turn claims that “Vaccines Do Not Cause Autism.”<sup>61</sup> Since HHS has chosen to incorporate the CDC’s website into the VIS as a resource, the information on that website regarding the relevant vaccine must be “based on available data and information.” *Id.* But, based on available data and information, as highlighted by the IOM, HHS cannot validly claim that “Vaccines Do Not Cause Autism.” Hence:

<sup>58</sup> <http://www.cdc.gov/p2/ITS-3-186.pdf>; <http://www.cdc.gov/p2/ITS-3-187.pdf>

<sup>59</sup> <http://vaccine-safety.amazonaws.com/WhitePaper/AlumAdjuvantAutism.pdf>

<sup>60</sup> [https://www.cdc.gov/vaccines/hcp/vis/viscurrent\\_vis.html](https://www.cdc.gov/vaccines/hcp/vis/viscurrent_vis.html)

<sup>61</sup> <https://www.cdc.gov/vaccinesafety/consent/autism.html>

- (9) Please confirm that HHS shall forthwith remove the claim that “Vaccines Do Not Cause Autism” from the CDC website, or alternatively, please identify the specific studies on which HHS bases its blanket claim that no vaccines cause autism?

#### VII. Refusal to Conduct Vaccinated Versus Unvaccinated Study

The only scientifically valid way to answer a large portion of the questions raised regarding vaccine safety would be a long-term, properly powered and controlled study comparing the rate of all adverse events between vaccinated children and completely unvaccinated children. This is the same type of study required by HHS for every drug pre-licensure. HHS has nonetheless refused to conduct any such study, even retrospectively.

The need for this study is highlighted by the results of a few recent limited vaccinated vs. unvaccinated studies.

Dr. Peter Aaby is renowned for studying and promoting vaccines in Africa with over 300 published studies.<sup>62</sup> In 2017, he published a study finding children vaccinated with DTP were 10 times more likely to die in the first 6 months of life than the unvaccinated.<sup>63</sup> Dr. Aaby’s study therefore concluded that: “All currently available evidence suggests that DTP vaccine may kill more children from other causes than it saves from diphtheria, tetanus or pertussis.”<sup>64</sup> More disturbing is that children vaccinated with DTP were dying from causes never associated with this vaccine, such as respiratory infections, diarrhea, and malaria.<sup>65</sup> This indicated that while DTP reduced the incidence of diphtheria, tetanus, and pertussis, it increased susceptibility to other infections.<sup>66</sup>

It is equally troubling that Dr. Abby’s study was based on data that had been collecting dust for over 30 years<sup>67</sup> This begs the question: what other serious vaccine injuries are we missing because of neglect to conduct proper vaccine safety science.

A pilot study comparing 650 vaccinated and unvaccinated homeschooled children in the United States provides a glimpse of the potential scope of vaccine harm.<sup>68</sup> The study found that, compared to completely-unvaccinated children, fully-vaccinated children had an increased risk

<sup>62</sup> <https://www.ncbi.nlm.nih.gov/pubmed/?term=+PETER+AABY+3BAW&acc=11411632>

<sup>63</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260569/> Dr. Aaby’s study was more reliable than other vaccine safety studies because the subjects were accurately matched. An increasingly recognized problem in vaccine safety studies is that subjects are typically not well-matched. People with pre-existing health problems are reluctant to receive a vaccine, and are therefore unwittingly used as controls. When this happens, the control group is sicker than the vaccine-exposed group at the outset of the study. Studies with this problem give wrong results, and make the vaccine look much safer than it really is. Dr. Aaby’s study was one of the few specifically designed to avoid this error.

<sup>64</sup> *Ibid.*

<sup>65</sup> *Ibid.*

<sup>66</sup> *Ibid.*

<sup>67</sup> *Ibid.*

<sup>68</sup> <http://www.oatesa.com/pdf/ITS-2.1.85.pdf>

of 390% for allergies, 420% for ADHD, 420% for autism, 290% for eczema, 520% for learning disabilities, and 370% for any neuro-developmental delay.<sup>69</sup> Fully-vaccinated pre-term infants had an increased risk of 1,450% for a neurodevelopmental disorder, which includes a learning disability, ADHD or autism, compared to completely unvaccinated preterm infants.<sup>70</sup>

Another recent study compared children receiving the flu shot with those receiving a saline injection in a prospective randomized double-blind study.<sup>71</sup> Both groups had the same rate of influenza but the group receiving the flu shot had a 440% increased rate of non-influenza infection.<sup>72</sup> Like the DTP study, the flu vaccine increased susceptibility to other infections.

A properly sized vaccinated versus unvaccinated study is necessary and possible. As stated by the IOM in 2013: "It is possible to make this comparison through analyses of patient information contained in large databases such as VSD."<sup>73</sup> Senior CDC Scientist, Dr. Thompson similarly stated this type of study can and "needs to be done" but that the CDC is "not doing what they should be doing because they're afraid to look for things that might be associated."<sup>74</sup> When vaccine makers are generating over \$33 billion in vaccine revenue annually and the CDC is spending over \$5 billion annually to promote and purchase vaccines, there is no justification for not performing this study.<sup>75</sup>

The 1986 Act expressly provides that you, as the Secretary, "shall promote the development of childhood vaccines that result in fewer and less adverse reactions" and "shall make or assure improvements in ... the ... labeling, warning, ... and research on vaccines, in order to reduce the risks of adverse reactions to vaccines." (42 U.S.C. § 300aa-27(a)(2).) Since comparing children receiving the vaccines recommended by the CDC with those that have not received any vaccines is the only scientifically valid way to assess the safety of the CDC's vaccine schedule:

**(10) Please advise whether HHS intends to forthwith conduct adequately powered and controlled prospective as well as retrospective studies comparing total health outcomes of**

<sup>69</sup> *Ibid.*

<sup>70</sup> <http://www.cdc.gov/pdfs/115-3-187.pdf>

<sup>71</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104712/>

<sup>72</sup> *Ibid.* See also [http://vaccine.safety.claremontnews.com/CDC\\_FOIA\\_Response\\_UnpublishedStudy.pdf](http://vaccine.safety.claremontnews.com/CDC_FOIA_Response_UnpublishedStudy.pdf) (The CDC in 2001 apparently conducted a narrow vaccinated versus unvaccinated study comparing children receiving the Hepatitis B vaccine during the first month of life versus those who did not. The results of this study were never released by the CDC, and an abstract of the study was only recently obtained under a FOIA request. Children vaccinated with Hepatitis B vaccine in the first month of life, compared to children receiving no vaccines in the first month of life, had an increased risk of 829% for ADHD, 762% for autism, 638% for ADD, 565% for tics, 498% for sleep disorders, and 206% for speech delays. Note that while the abstract discusses comparing thimerosal exposure, since the only vaccine recommended by one month of age was Hepatitis B, and since only thimerosal containing Hepatitis B vaccine was available at the time of this study, this study appears to have primarily compared children receiving Hepatitis B with children that did not receive this vaccine.)

<sup>73</sup> <https://www.cdc.gov/od/113663/shapter/2013>

<sup>74</sup> <https://www.cdc.gov/od/113663/shapter/2013>

<sup>75</sup> <https://www.hhs.gov/policy/foia/files/2017-budget-in-brief.pdf>; <https://www.kynews.com/market-research/philip-schiff/vaccine-technologies-market-report-philip-schiff.html>

fully/partially vaccinated children with completely unvaccinated children?

### VIII. Reducing Conflicts of Interest at HHS

The 1986 Act created a system in which vaccines are licensed, recommended, encouraged, subsidized, and defended by HHS. The 1986 Act's scheme thus places HHS in charge of two competing duties. On one hand, HHS is responsible for vaccine safety. On the other hand, HHS is required to promote vaccine uptake and defend against any claim they cause any harm.

Regrettably, it appears that HHS has chosen to focus almost entirely on its vaccine promotion and defense function to such a degree that it has essentially abandoned its vaccine safety function. To restore balance, HHS must take serious steps to create an "ethics firewall" between these competing functions. HHS also must take action with regard to its vaccine committee members and employees that have conflicts with vaccine makers.

**HHS Licenses & Recommends Vaccines.** With regard to the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC), which effectively decides whether to license a vaccine, in 2000 the U.S. House Committee on Government Reform (the Committee) "determined that conflict of interest rules employed by the FDA and the CDC have been weak, enforcement has been lax, and committee members with substantial ties to pharmaceutical companies have been given waivers to participate in committee proceedings."<sup>76</sup> The Committee concluded of the VRBPAC: "The overwhelming majority of members, both voting members and consultants, have substantial ties to the pharmaceutical industry."<sup>77</sup>

With regard to the CDC's Advisory Committee on Immunization Practices (ACIP), which effectively decides whether to universally recommend a pediatric vaccine, the Committee found that ACIP members routinely fail to disclose conflicts with vaccine makers and when conflicts are disclosed "[t]he CDC grants blanket waivers to the ACIP members each year that allow them to deliberate on any subject, regardless of their conflicts."<sup>78</sup> The Committee drew focus on the vaccine most recently approved by the ACIP and found extensive and troubling conflicts of interest for most the ACIP members voting to recommend its universal use for children.<sup>79</sup> The Committee was further concerned that "ACIP liaison representatives have numerous ties to

---

<sup>76</sup> [http://vaccinesafetycommittee.org/pdfs/Conflicts\\_Conf\\_Rep\\_may04.pdf](http://vaccinesafetycommittee.org/pdfs/Conflicts_Conf_Rep_may04.pdf) (For instance, "3 out of 5 FDA advisory committee [VRBPAC] members who voted to approve the rotavirus vaccine in December 1997 (then the most recently approved vaccine by the VRBPAC) had significant financial ties to pharmaceutical companies that were developing different versions of the vaccine.")

<sup>77</sup> *Ibid.*

<sup>78</sup> *Ibid.*

<sup>79</sup> *Ibid.* (The Committee's findings were that: (1) The chairman served on Merck's Immunization Advisory Board, (2) another member, who shared the patent on a rotavirus vaccine, had a \$350,000 grant from Merck to develop the vaccine, and was a consultant for Merck; (3) another member was under contract with the Merck Vaccine Division, a principal investigator for SmithKline and received funds from various vaccine makers; (4) another member received a salary and other payments from Merck; (5) another member participated in vaccine studies with Merck, Wyeth, and SmithKline, and (6) another member received grants from Merck and SmithKline.)

vaccine manufacturers” but act like voting members of ACIP.<sup>80</sup> The Committee further took issue with the extensive conflicts of interests of members of ACIP’s working groups which convene behind closed doors and whose recommendations are typically rubber stamped by the ACIP.<sup>81</sup> The Committee concluded that ACIP reflected “a system where government officials make crucial decisions affecting American children without the advice and consent of the governed.”<sup>82</sup>

Despite the concerns the Committee expressed in its 2000 report, not much changed. A December 2009 report by the HHS Office of Inspector General found that the “CDC had a systemic lack of oversight of the ethics program for SGEs [a.k.a. committee members].”<sup>83</sup> For example, “Most of the experts who served on advisory panels in 2007 to evaluate vaccines for flu and cervical cancer had potential conflicts that were never resolved.”<sup>84</sup>

In fact, the Inspector General found that the “CDC certified [conflict disclosure forms] with at least one omission in 2007 for 97 percent ... of SGEs,” “58 percent ... of SGEs had at least one potential conflict of interest that CDC did not identify,” and when the CDC identified a conflict, it improperly granted broad waivers despite being castigated for this improper practice in 2000.<sup>85</sup> Even worse, “32 percent ... of SGEs ... had at least one potential conflict of interest that CDC identified but did not resolve” and 13 percent of SGEs were allowed to participate in committee meetings without even having a conflict disclosure form on file.<sup>86</sup>

As the system is set up, an ACIP vote to recommend a vaccine, grants a vaccine manufacturer a liability-free market of 78 million American children, who are legally compelled to receive the vaccine, and billions of taxpayer dollars guaranteeing payment. In such a system, an ACIP vote must be completely insulated from any influence by the vaccine manufacturer. Instead, the opposite appears to be the norm.

**HHS Promotes Vaccines.** Moreover, while the CDC states on its website -- not less than 130 times -- that “CDC does not accept commercial support,” this is simply not true.<sup>87</sup> For example, the British Medical Journal reported in 2015 that: “Despite the agency’s disclaimer, the CDC does receive millions of dollars in industry gifts and funding, both directly and indirectly, and several recent CDC actions and recommendations have raised questions about the science it cites, the clinical guidelines it promotes, and the money it is taking.”<sup>88</sup> As another example, pharmaceutical companies and other private entities, through the “CDC Foundation,” can create and fund programs at the CDC (over half a billion dollars’ worth to-date), endow positions at the

---

<sup>80</sup> *Ibid.*

<sup>81</sup> *Ibid.*

<sup>82</sup> *Ibid.*

<sup>83</sup> <https://oig.hhs.gov/eoip/records/0147-03360.pdf>

<sup>84</sup> <http://www.fiercebiotech.com/2010/12/18/hesl0/policy/1806.html>

<sup>85</sup> <https://oig.hhs.gov/eoip/records/0147-03360.pdf> (Splicing down this 58% of unidentified conflicts, 40% involved employment or grants, 13% involved equity ownership, and 5% involved consulting.)

<sup>86</sup> *Ibid.*

<sup>87</sup> <https://search.cdc.gov/search/?query=%22cdc%20does%20not%20accept%20commercial%20support%22&offset=1&size=25%26&affiliate=cdc-main>

<sup>88</sup> <http://www.bmj.com/content/350/bmj.g2162>



unvaccinated children, despite all the resources at its disposal.<sup>94</sup> It is no wonder a single injured child's claim faces a high likelihood of failure in the VICP.

Many parents, doctors and scientists, as well as politicians, are legitimately concerned about the process whereby vaccines are licensed, recommended, promoted and defended by the same department. This is not because of any conspiracy, or belief an insidious intent. Rather, this system eliminates the incentive, and in fact creates a disincentive for HHS and vaccine makers, to conduct research to uncover long term chronic conditions, including the immune and neurological system disorders, which can result from the current vaccine schedule.

The 1986 Act expressly provides that you, as the Secretary, have at least equal and arguably greater responsibility for vaccine safety than for vaccine promotion. (42 U.S.C. §§ 300aa-2, 300aa-27.) In accordance with this statutory responsibility:

(11) Please advise if you will:

- a. prohibit conflict waivers for members of HHS's vaccine committees (ACIP, VRBPAC, NVAC & ACCV)?
- b. prohibit HHS vaccine committee members or HHS employees with duties involving vaccines from accepting any compensation from a vaccine maker for five years?
- c. require that vaccine safety advocates comprise half of HHS's vaccine committees?
- d. allocate toward vaccine safety an amount at least equal to 50% of HHS's budget for promoting/purchasing vaccines?
- e. support the creation of a vaccine safety department independent of HHS?
- f. support the repeal of the 1986 Act to the extent it grants immunity to pharmaceutical companies for injuries caused by their vaccine products?

## **IX. Conclusion**

HHS can do better. With hundreds of vaccines in the pipeline it must do better. Children susceptible to vaccine injury are as deserving of protection as any other child. Avoiding injury to these children is not only a moral and ethical duty, but will in fact strengthen the vaccine program. Every parent that does not witness their child suffer a serious reaction after vaccination, such as a seizure or paralysis, is another parent that will not add their voice to the growing chorus of parents opposed to HHS's vaccine program due to safety concerns.

---


<sup>94</sup> See Section VII above.

Unless HHS performs its vital statutory obligations regarding vaccine safety, and until a frank conversation is possible regarding vaccine safety, children susceptible to vaccine injury will not be protected from such injuries. Nor will children injured by vaccines be able to access the services they need. We can do far better in protecting and serving children who are susceptible or succumb to serious injuries from vaccination. The first step in avoiding these harms and helping children already harmed is admitting there are deficiencies and working diligently to improve vaccine safety.

We respectfully request your attention to the important concerns outlined above and hope you agree that addressing these concerns is in everyone's best interest. These, in fact, reflect nothing more than what Congress already explicitly recognized when passing the 1986 Act: vaccines can and do cause serious injury and HHS needs to work diligently to identify and reduce these harms. If you would like to meet and discuss the foregoing, we would welcome that opportunity and hope to work cooperatively to address these issues.

If that is not possible, Congress, as a final resort to assure vaccine safety, authorized a "civil action ... against the Secretary where there is alleged a failure of the Secretary to perform any act or duty under" the 1986 Act. (42 U.S.C. § 300aa-31(a).) We are prepared to authorize such an action and this letter constitutes the notice required by 42 U.S.C. § 300aa-31(b). It is, however, our hope that the vaccine safety issues identified herein can be resolved cooperatively, with all interested parties working together toward the common goal of vaccine safety entrusted to HHS under the 1986 Act.

Very truly yours,



Del Bigtree

cc: See Appendix A.  
Enclosures: Appendices A to C.

# Appendix A

A Voice For Choice  
A Voice For Choice Advocacy  
Christina Hildebrand, President  
530 Showers Drive, Suite 7404  
Mountain View, CA 94040

Alliance For Natural Health  
Gretchen DuBeau, President  
3525 Piedmont Road NE B6-310  
Atlanta, GA 30305

Arizona Coalition Against Mandated  
Vaccines  
Kelsey Davis, President  
Gilbert, AZ 85212

Autism Action Network  
John Gilmore, President  
550 East Chester Street  
Long Beach, NY 11561

Autism Giving Tree  
Christina Stafford, M.Ed., BCBA, LBS,  
President  
660 'W' Street  
King of Prussia, PA 19406

AutismOne  
Ed Arranga, President  
1816 West Houston Avenue  
Fullerton, CA 92833

The Canary Party  
Jennifer Larson, President  
6533 Flying Cloud Drive, Suite 1200  
Eden Prairie, MN 55344

Colorado Coalition for Vaccine Choice  
Fran Sincere, President  
125 S. Zephyr  
Lakewood, CO 80226

DAIR Foundation  
Dawn Loughborough, President  
10200 US HWY 290 West  
Austin, TX 78736

Elizabeth Birt Center for Autism Law and  
Advocacy  
Kim Mack Rosenberg, President  
200 Cabrini Boulevard, Suite 66  
New York, NY 10033

Enriched Parenting  
Rebecca Fleischman, President  
1208 Avenue M, Suite 2323  
Brooklyn, NY 11230

Focus for Health Foundation  
Shannon Mulvihill, R.N., Executive Director  
776 Mountain Boulevard, Suite 202  
Watchung, NJ 07069

Georgia Coalition for Vaccine Choice  
Sandi Marcus, Founder/CEO  
P.O. Box 45  
Silver Creek, GA 30173

Health Choice  
Mark Blaxil, President  
6533 Flying Cloud Drive, Suite 1200  
Eden Prairie, MN 55344

Health Choice Massachusetts  
Candice Edwards, President  
P.O. Box 175  
Manchaug, MA 01526

Indiana for Medical Freedom  
Melissa Sura, President  
5424 Grapevine Drive  
Indianapolis, IN 46235

Health Choice Maryland  
Emily Tarsell, President  
1501 Sulgrave Avenue, Suite 208  
Baltimore, MD 21209

Informed Choice Washington  
Jena Dalpez, President  
14106 93rd Avenue NE  
Kirkland, WA 98034

Health Choice Connecticut  
Dr. Elissa Diamond Fields, President  
P.O. Box 29  
Roxbury, CT 06783

Kentucky Vaccine Rights Coalition  
Jennifer Bengé & Ashley Kennedy, Co-  
Presidents  
899 Corinth Road  
Corbin, KY 40701

Health Freedom Florida  
Dr. Ryan Fenn & MacKenzie Fraser, Co-  
Presidents  
153 Ivernia Loop  
Tallahassee, FL 32312

Know The Vax  
Angela Gallagher, President  
4553 Aldrich Avenue North  
Minneapolis, MN 55412

Health Freedom Idaho  
Miste Gardner Karlfeldt, President  
1045 S Ancona Ave Ste 140  
Eagle, ID 83616

Learn the Risk  
Brandy Vaughan, President  
3463 State Street, Suite 182  
Santa Barbara, CA 93105

Healthcare Freedom Hawaii  
Jessica McCormick &  
Natasha Sky, Co-Directors  
Mililani, HI 96789

Louisiana Parents for Vaccine Rights  
Melisha Dooley &  
Sunny Dixon, Co-Directors  
413 Toby Lane  
Metairie, LA 70003

Illinois Coalition for Informed Consent  
Jen Suter &  
Danielle Olson, Co-Directors  
Jacksonville, IL 62650

Maine Coalition for Vaccine Choice  
Ginger Taylor, Director  
11 High Street  
Brunswick, ME 04011

March Against Monsanto  
Tami Canal, President  
7878 South 1960 East  
South Weber, UT 84405

Moms Across America  
Zen Honeycutt, President  
24000 Alicia Parkway, Suite 17-236  
Mission Viejo, CA 92691

Michigan for Vaccine Choice  
Suzanne M. Waltman, President  
22615 Francis Street  
St. Clair Shores, MI 48082

Montanans For Medical Freedom  
Edna Kent, Director  
PO Box 1443  
Florence, MT 59833

Minnesota Natural Health Coalition  
Lee Beaty, President  
1043 Grand Ave, Suite 317  
St. Paul MN 55105

My Kids, My Choice  
Rita Palma, President  
2 Purdy Avenue  
Baypoint, NY 11705

Minnesota Natural Health Legal Reform  
Project  
Leo Cashman, President  
1043 Grand Ave, Suite 317  
St. Paul, MN 55105

National Health Freedom Action  
Jerri Johnson, President  
PMB 218, 2136 Ford Parkway  
St. Paul, MN 55116

Minnesota Vaccine Freedom Coalition  
Angela Gallagher, President  
4553 Aldrich Avenue North  
Minneapolis, MN 55412

National Health Freedom Coalition  
Roseanne Lindsay, President  
PMB 218, 2136 Ford Parkway  
St. Paul, MN 55116

Mississippi Parents for Vaccine Rights  
MaryJo Perry, President  
P.O. Box 141  
Pelahatchie, MS 39145

New York Alliance for Vaccine Rights  
Aimee Villella McBride & Maria Gavriel,  
Co-Presidents  
550 East Chester Street  
Long Beach, NY 11561

Missouri Parents Against Vaccines  
Janessa Baake & Kendal Bourne, Co-  
Presidents  
323 N. Fox Ridge Drive, Suite 204  
Raymore, MO 64083

Ohio Advocates for Medical Freedom  
Robert M. Wise, President  
P.O. Box 1236  
Hartville, OH 44632

Oklahomans for Vaccine and Health Choice  
Liza Greve, President  
P.O. Box 721356  
Norman, OK 73070

Spectrum Revolution  
Catharine Layton, President  
357 S. Earlham Street  
Orange, CA 92869

Organic Consumers Association  
Ronnie Cummins, CEO  
6771 South Silver Hill Dr.  
Finland, MN 55603

Tennessee Coalition for Vaccine Choice  
Kristen Odom-Holland, President  
P.O. Box 4508  
Chattanooga, TN 37405

Parents United 4 Kids  
Stefanie Fetzer & Shawna Lambert, Co-  
Presidents  
2925 Bonanza  
San Clemente, CA 92673

Vaccine Injury Awareness League  
Michelle Ford, President  
10866 Washington Blvd, Suite 65  
Culver City, CA 90232

People Advocating Vaccine Education, Inc.  
Lisa Jillani, CEO  
P.O. Box 690712  
Charlotte, NC 28227

Vaccine Safety Council Minnesota  
Patti Carroll, President  
6533 Flying Cloud Drive, Suite 1200  
Eden Prairie, MN 55344

Physicians for Informed Consent  
Dr. Shira Miller, Executive Director  
13749 Riverside Drive  
Sherman Oaks, CA 91423

Vermont Coalition for Vaccine Choice  
Jennifer Stella, President  
P.O. Box 74  
Waitsfield, VT 05673

Rogue Recovery  
Tyler Dahm, President  
3221 West 96th Avenue  
Westminster, CO 80031

Virginians for Health Freedom  
Deborah Hommer, President  
P.O. Box 2015  
Spotsylvania, VA 22553

South Carolina Health Coalition  
Jennifer Black & Rebekah Watson, Co-  
Presidents  
1754 Woodruff Road, Suite 112  
Greenville, SC 29607

West Virginians for Health Freedom  
Dr. Chanda Adkins, Director  
108 Yorktown Court  
Beckley, WV 25801

Weston A. Price Foundation  
Sally Fallon Morell, President  
PMB 106-380, 4200 Wisconsin Avenue NW  
Washington, D.C., 20016

World Mercury Project  
Robert F. Kennedy, Jr., Chairman  
1227 North Peachtree Parkway, Suite 202  
Peachtree City, GA 3026

# Appendix B

Adverse Effects of Vaccines: Evidence and Causality

# Adverse Effects of Vaccines

*Evidence and Causality*

Committee to Review Adverse Effects of Vaccines  
Board on Population Health and Public Health Practice  
Kathleen Stratton, Andrew Ford, Erin Rusch, and Ellen Wright Clayton,  
*Editors*

INSTITUTE OF MEDICINE  
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS  
Washington, D.C.  
[www.nap.edu](http://www.nap.edu)

Copyright National Academy of Sciences. All rights reserved.

*Weight of Epidemiologic Evidence*

*The epidemiologic evidence is insufficient or absent to assess an association between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and ataxia.*

**Mechanistic Evidence**

The committee identified one publication reporting the development of ataxia after the administration of DTaP vaccine. Kubota and Takahashi (2008) did not provide evidence of causality beyond a temporal relationship of 2 days between vaccine administration and development of cerebellar symptoms leading to a diagnosis of acute cerebellar ataxia. The publication did not contribute to the weight of mechanistic evidence.

*Weight of Mechanistic Evidence*

*The committee assesses the mechanistic evidence regarding an association between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and ataxia as lacking.*

**Causality Conclusion**

**Conclusion 10.5:** The evidence is inadequate to accept or reject a causal relationship between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and ataxia.

**AUTISM**

**Epidemiologic Evidence**

The committee reviewed one study to evaluate the risk of autism after the administration of DTaP vaccine. This one study (Geier and Geier, 2004) was not considered in the weight of epidemiologic evidence because it provided data from a passive surveillance system and lacked an unvaccinated comparison population.

*Weight of Epidemiologic Evidence*

*The epidemiologic evidence is insufficient or absent to assess an association between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and autism.*

#### Mechanistic Evidence

The committee did not identify literature reporting clinical, diagnostic, or experimental evidence of autism after the administration of vaccines containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens alone or in combination.

#### Weight of Mechanistic Evidence

*The committee assesses the mechanistic evidence regarding an association between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and autism as lacking.*

#### Causality Conclusion

**Conclusion 10.6:** The evidence is inadequate to accept or reject a causal relationship between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccine and autism.

### ACUTE DISSEMINATED ENCEPHALOMYELITIS

#### Epidemiologic Evidence

No studies were identified in the literature for the committee to evaluate the risk of acute disseminated encephalomyelitis (ADEM) after the administration of vaccines containing diphtheria toxoid, tetanus toxoid, or acellular pertussis antigens alone or in combination.

#### Weight of Epidemiologic Evidence

*The epidemiologic evidence is insufficient or absent to assess an association between diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccines and ADEM.*

#### Mechanistic Evidence

The committee identified five publications of ADEM developing after the administration of vaccines containing diphtheria toxoid and tetanus toxoid antigens alone or in combination. Four publications did not provide evidence beyond temporality, one of which was deemed too short based on the possible mechanisms involved (Abdul-Ghaffar and Achar, 1994; Bolukbasi and Ozmenoglu, 1999; Hamdon and Raymond, 2003; Rogalewski et al., 2007). In addition, Rogalewski et al. (2007) reported the administration of vaccines against hepatitis B, hepatitis A, and poliovirus in

# Appendix C



a place of mind  
THE UNIVERSITY OF BRITISH COLUMBIA

Faculty of Medicine  
Department of Ophthalmology  
& Visual Sciences  
Shaw Laboratory  
828 West 10th Avenue, Room 386  
Vancouver BC Canada V5Z 1L8

Phone 604 875 4111 local 68375  
Fax 604 875 4376  
[www.neuradynamic.ubc.ca](http://www.neuradynamic.ubc.ca)

June 24, 2017

United States Department of Health & Human Services  
National Institutes of Health  
Food & Drug Administration  
Centers for Disease Control & Prevention  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Re: *Aluminum Adjuvants*

Dear Directors:

I am writing to you in regard to aluminum adjuvants in vaccines. This subject is one my laboratory works on intensively and therefore one where I feel that I have some expertise. In particular, we have studied the impact of aluminum adjuvants in animal models of neurological disease, including autism spectrum disorder (ASD). Our relevant studies on the general topic of aluminum neurotoxicity in general and specifically in regard to adjuvants are cited below.

These studies and the broader existing literature regarding aluminum toxicity, lead almost invariably to the conclusion that aluminum in any chemical form is always neurotoxic when administered to humans. Further, I am convinced that aluminum adjuvants in vaccines may contribute to neurological disorders across the lifespan. In adults, such adjuvant may induce macrophagic myofasciitis, a disease with neuropathological aspects. In children, there is growing evidence that aluminum adjuvants may disrupt developmental processes in the central nervous system and therefore contribute to ASD in susceptible children.

Despite the foregoing, the safety of aluminum adjuvants in vaccines has not been properly studied in humans even though, pursuant to the recommended vaccine schedule published by the Centers for Disease Control (CDC), a baby may be injected with up to 3,675 micrograms of aluminum adjuvant by six months of age.

In regard to the above, it is my belief that the CDC's claim on its website that "Vaccines Do Not Cause Autism" is wholly unsupported. Given this, I remain convinced that much more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is warranted and should be a research priority for the NIH and other funding bodies.

Yours sincerely,

Christopher A. Shaw, Ph.D  
Professor  
Dept. of Ophthalmology and Visual Sciences  
University of British Columbia  
828 W. 10<sup>th</sup> Ave.  
Vancouver, British Columbia  
Canada, V5Z 1M9  
Tel: 604-875-4111 (ext. 68373)  
Email: [cashawlab@gmail.com](mailto:cashawlab@gmail.com)



#### Relevant Publications (Shaw Laboratory)

1. Crepeaux G, Eidi H, David MO, Baba-Amer Y, Tzavara E, Giros B, Authier FJ, Exley C, Shaw CA, Cadusseau J, Gherardi RK. Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective dose neurotoxicity. *Toxicology*. 375:48-57. (2016).
2. Crepeaux G, Eidi H, David M-O, Tzavara E, Giros B, Exley C, Curmi PA, Shaw CA, Gherardi RK, Cadusseau J. Highly delayed systemic translocation of aluminium-based adjuvant in CD1 mice following intramuscular injections. *J. Inorg. Biochem.* 152:199-205. (2015).
3. Shaw CA, Li D, Tomljenovic L. Are there negative CNS impacts of aluminum adjuvants in vaccines and immunotherapy? *Immunotherapy*. 6 (10):1055-1071. (2014).
4. Shaw CA, Seneff S, Kette SD, Tomljenovic L, Oller Jr JW, Davidson RM. Aluminum-induced entropy in biological systems: Implications for neurological disease. *J Toxicology*. Volume 2014, Article ID 491316. (2014).
5. Shaw CA, Kette SD, Davidson RM, Seneff S. Aluminum's role in CNS-immune system interactions leading to neurological disorders. *Immunome Res*. 9:1.
6. Shaw CA, Marler TE. Aluminum and the human diet revisited. In: *Communicative & Integrative Biology: London Bioscience*. 6:e26369. (2013).
7. Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. *Immunol Res*. (2013).
8. Shaw CA, Li Y, Tomljenovic L. Administration of aluminum to neonatal mice in vaccine in vaccine-relevant amounts is associated with adverse long term neurological outcomes. *J Inorg Chem*. (2013).
9. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. *Lupus*. 21:223-230. (2012).
10. Tomljenovic L and Shaw CA. Editorial, Special Issue: The Biochemistry/Toxicity of Aluminum. *Current Inorganic Chemistry*. 2(1): 1-2. (2012).
11. Tomljenovic L and Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? *J Inorg Biochem*. 105(11):1489-99. (2011).
12. Tomljenovic L and Shaw CA. Aluminum vaccine adjuvants: Are they safe? *Current Medicinal Chemistry*. 18:2630 – 2637. (2011).
13. Shaw CA and Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. *J Inorganic Biochem*. 103 (11): 1555-62. (2009).
14. Petrik MS, Wong MC, Tabata RC, Garry RF, and Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. *J Neuromolecular Medicine* 9: 83-100. (2007).

June 15, 2017

United States Department of Health & Human Services  
National Institutes of Health  
Food & Drug Administration  
Centers for Disease Control & Prevention  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Re: *Aluminum Adjuvants*

Dear Directors:

UMR U955 INSERM / UPEC

Team 10

« Biology of the neuromuscular  
system »

Fred Relais, director

François Jérôme Authier, co-director

Romain Gherardi, former director

Tel. +33 (0)1 49 81 27 42

Fax. +33 (0)1 49 81 27 33


romain.gherardi@inserm.fr

I am an expert in the field of aluminum adjuvants toxicity in humans and animal models. I have been working in this field since the initial description of the Al vaccine-induced macrophagic myofasciitis in 1998. Since that time I have written 40 peer-reviewed scientific publications and one book on this subject.

I strongly support the contention that aluminum adjuvants in vaccines may have a role in the etiology of autism spectrum disorder (ASD). My view is founded on a significant and burgeoning body of peer-reviewed scientific evidence which makes the link between ASD and exposure to aluminum through vaccinations and other sources. Examples of this literature from my own group are detailed below and I urge the HHS to take them into consideration in forming any future opinion on the safety of aluminum adjuvants in vaccines.

The Center for Disease Control's claim on its website that "Vaccines Do Not Cause Autism" is unsupported with respect to aluminum adjuvants and this claim stifles the important research to determine the safety of aluminum adjuvants used in vaccines. As an expert in the field of aluminum adjuvants and aluminum toxicity I solemnly declare that more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is essential and urgently required.

Yours very sincerely



Romain K. Gherardi  
Professor, Neuromuscular Pathology Expert Centre  
University Paris-Est, INSERM U955-E10,  
Henri Mondor hospital, Créteil France  
Contact at the hospital  
Tel 00 (33) 1 49812746  
[romain.gherardi@hmn.aphp.fr](mailto:romain.gherardi@hmn.aphp.fr)

*Selection of significant publications from our group in the field*

Gherardi R. Toxic Story: deux ou trois vérités embarrassantes sur les adjuvants des vaccins. Actes Sud (publisher), Paris, 2016, 250 pages

Crépeaux G, Eidi H, David MO, Baba-Amer Y, Travara E, Giras B, Authier FJ, Exley C, Shaw CA, Cadusseau J, Gherardi RK. Non linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity. *Toxicology*. 2017 Jan 15;375:48-57.

Masson JD, Crépeaux G, Authier FJ, Exley C, Gherardi RK. [Critical analysis of reference studies on aluminium-based adjuvants toxicokinetics]. *Ann Pharm Fr*. 2017 May 30. pii: S0003-4509(17)30033-0.

Van Der Gucht A, Aouni Sebaiti M, Guedj E, Aouizerate J, Yara S, Gherardi RK, Evangelista E, Chalaye J, Cottureau AS, Verger A, Bachoud-Levi AC, Abulizi M, Itti E, Authier FJ. Brain (18)F-FDG PET Metabolic Abnormalities in Patients with Long-Lasting Macrophagic Myofasciitis. *J Nucl Med*. 2017 Mar;58(3):492-498.

Crépeaux G, Eidi H, David MO, Travara E, Giras B, Exley C, Curmi PA, Shaw CA, Gherardi RK, Cadusseau J. Highly delayed systemic translocation of aluminium-based adjuvant in CD1 mice following intramuscular injections. *J Inorg Biochem*. 2015 Nov;152:199-205.

Eidi H, David MO, Crépeaux G, Henry L, Joshi V, Berger MH, Sennour M, Cadusseau J, Gherardi RK, Curmi PA. Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition. *BMC Med*. 2015 Jun 17;13:144.

Van Der Gucht A, Aouni Sebaiti M, Itti E, Aouizerate J, Evangelista E, Chalaye J, Gherardi RK, Ragunathan-Thangarajah N, Bachoud-Levi AC, Authier FJ. Neuropsychological Correlates of Brain Perfusion SPECT in Patients with Macrophagic Myofasciitis. *PLoS One*. 2015 Jun 1;10(6):e0128353.

Khan Z, Combadière C, Authier FJ, Itier V, Lux F, Exley C, Mahrouf-Yorgov M, Decrouy X, Moretto P, Tillement O, Gherardi RK, Cadusseau J. Slow CC12-dependent translocation of biopersistent particles from muscle to brain. *BMC Med*. 2013 Apr 4;11:99.

Couette M, Soisse MF, Maisson P, Brugieres P, Casaro P, Chevalier X, Gherardi RK, Bachoud-Levi AC, Authier FJ. Long-term persistence of vaccine-derived aluminium hydroxide is associated with chronic cognitive dysfunction. *J Inorg Biochem*. 2009 Nov;103(11):1571-8.

Authier FJ, Souvat S, Christov C, Chariot P, Raisbeck G, Poran MF, Ylou F, Gherardi R. AIOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background. *Neuromuscul Disord*. 2006 May;16(5):347-52.

Authier FJ, Souvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. *Arthritis Rheum*. 2003 Feb;48(2):569-70.

Gherardi RK. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome]. *Rev Neurol (Paris)*. 2003 Feb;159(2):162-4. Review. French.

Authier FJ, Cherin P, Creunge A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maissonobe T, Coquet M, Degos JD, Gherardi RK. Central nervous system disease in patients with macrophagic myofasciitis. *Brain*. 2001 May;124(Pt 5):974-83.

Gherardi RK, Coquet M, Cherin P, Bélec L, Moretto P, Dreyfus PA, Pelkssier JF, Chariot P, Authier FJ. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *Brain*. 2001 Sep;124(Pt 9):1821-31.

Gherardi RK, Coquet M, Cherin P, Authier FJ, Laforêt P, Bélec L, Figarella-Branger D, Mussini JM, Pelkssier JF, Fardeau M. Macrophagic myofasciitis: an emerging entity. *Lancet*. 1998 Aug 1;352(9125):347-52.



## Innovations in Inorganic and Materials Chemistry

Tel: 01782 734080

Fax: 01782 712378

e-mail: [g.exley@keele.ac.uk](mailto:g.exley@keele.ac.uk)

<http://www.keele.ac.uk/aluminium>

June 15, 2017

United States Department of Health & Human Services  
National Institutes of Health  
Food & Drug Administration  
Centers for Disease Control & Prevention  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Re: *Aluminum Adjuvants*

Dear Directors:

I am an expert in the field of aluminum adjuvants and aluminum toxicity. I have been working in this field for more than 30 years during which time I have written in excess of 150 peer-reviewed scientific publications on this subject.

I strongly support the contention that aluminum adjuvants in vaccines may have a role in the etiology of autism spectrum disorder (ASD). My view is founded on a significant and burgeoning body of peer-reviewed scientific evidence which makes the link between ASD and exposure to aluminum through vaccinations and other sources. Examples of this literature from my own group are detailed below and I urge the HHS to take them into consideration in forming any future opinion on the safety of aluminum adjuvants in vaccines.

The Center for Disease Control's claim on its website that "Vaccines Do Not Cause Autism" is unsupported with respect to aluminum adjuvants and this claim stifles the important research to determine the safety of aluminum adjuvants used in vaccines. As an expert in the field of aluminum adjuvants and aluminum toxicity I solemnly declare that more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is essential and urgently required.

Telephone number +44 (0)1782) 584211

Fax +44 (0)1782) 712378

Keele University, Staffordshire, ST5 5BG United Kingdom  
Telephone number +44 (0)1782) 621111 <http://www.keele.ac.uk>

IR#0129\_Appeal Production\_FDA000189

Yours faithfully



Christopher Exley PhD  
Professor in Bioinorganic Chemistry

Honorary Professor, University of the Highlands and Islands

**List of Recent, Relevant and Significant Publications From Our Group**

- Exley C, Siesjö P & Eriksson H (2010) The immunobiology of aluminium adjuvants: how do they really work? *Trends in Immunology* 31, 103-109.
- Exley C and House E (2011) Aluminium in the human brain. *Monatshefte für Chemie - Chemical Monthly* 142, 357-363.
- House E, Esiri M, Forster G, Ince PG and Exley C (2012) Aluminium, iron and copper in human brain tissues donated to the medical research council's cognitive function and ageing study. *Metallomics* 4, 56-65.
- Exley C (2011) Aluminium-based adjuvants should not be used as placebos in clinical trials. *Vaccine* 29, 9289.
- Exley C (2012) When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes. *Vaccine* 30, 2042.
- Exley C (2012) The coordination chemistry of aluminium in neurodegenerative disease. *Coordination Chemistry Reviews* 256, 2142-2146.
- Exley C, House E, Polwart A and Esiri MM (2012) Brain burdens of aluminium, iron and copper and their relationships with amyloid beta pathology in 60 human brains. *Journal of Alzheimer's Disease* 31, 725-730.
- Davenward S, Bentham P, Wright J, Crome P, Job, D, Polwart A and Exley C (2013) Silicon-rich mineral water as a non-invasive test of the 'aluminium hypothesis' in Alzheimer's disease. *Journal of Alzheimer's Disease* 33, 423-430.
- Khan Z, Combadière C, Authier FJ, Itier V, Lux F, Exley C, Mahrouf-Yorgov M, Decrouy X, Moretto P, Tillement O, Gherardi RK, and Cadusseau J (2013) Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. *BMC Medicine* 11:99.
- Exley C (2013) Human exposure to aluminium. *Environmental Science: Processes and Impacts* 15, 1807-1816.
- Ohlsson L, Exley C, Darabi A, Sandén E, Siesjö P and Eriksson H (2013) Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells. *Journal of Inorganic Biochemistry* 128, 229-236.
- Exley C (2014) Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. *Allergy, Asthma and Clinical Immunology* 10, 4.
- Exley C and Vickers T (2014) Elevated brain aluminium and early onset Alzheimer's disease in an individual occupationally exposed to aluminium: a case report. *Journal of Medical Case Reports* 8,41.
- Exley C (2014) What is the risk of aluminium as a neurotoxin? *Expert Review of Neurotherapeutics* 14, 589-591.
- Mold M, Eriksson H, Siesjö P, Darabi A, Shardlow E and Exley C (2014) Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. *Scientific Reports* 4, 6287.

Telephone number +44 (0)1782 584211  
Fax +44 (0)1782 712378

Keele University, Staffordshire, ST5 5BG United Kingdom  
Telephone number +44 (0)1782 621111 <http://www.keele.ac.uk>

IR#0129\_Appeal Production\_FDA000190

Exley C (2014) Why industry propaganda and political interference cannot disguise the inevitable role played by human exposure to aluminium in neurodegenerative diseases, including Alzheimer's disease. *Frontiers in Neurology* 5:212. doi: 10.3389/fneur.2014.00212.

Crépeaux G, Eidi H, David M-O, Tzavara E, Giras B, Exley C, Curmi PA, Shaw CA, Gherardi RK and Cadusseau J (2015) Highly delayed systemic translocation of aluminium-based adjuvant in CD1 mice following intramuscular injections. *Journal of Inorganic Biochemistry* 152, 199-205.

Exley C (2016) The toxicity of aluminium in humans. *Morphologie* 100, 51-55.

Mirza A, King A, Troakes C and Exley C (2016) The identification of aluminium in human brain tissue using lumogallion and fluorescence microscopy. *Journal of Alzheimer's Disease* 54, 1333-1338.

Mold M, Shardlow E and Exley C (2016) Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically-approved human vaccinations. *Scientific Reports* 6:31578.

Mirza A, King A, Troakes C and Exley C (2017) Aluminium in brain tissue in familial Alzheimer's disease. *Journal of Trace Elements in Medicine and Biology* 40, 30-36.

Shardlow E, Mold M and Exley C (2017) From stock bottle to vaccine: Elucidating the particle size distributions of aluminium adjuvants using dynamic light scattering. *Frontiers in Chemistry* 4, 48.

Exley C (2017) Aluminium should now be considered a primary aetiological factor in Alzheimer's disease. *Journal of Alzheimer's Disease Reports* 1, 23-25.

Telephone number +44 (0)1782 584211  
Fax +44 (0)1782 712378

---

Keele University, Staffordshire, ST5 5BG United Kingdom  
Telephone number +44 (0)1782 621111 <http://www.keele.ac.uk>

IR#0129\_Appeal Production\_FDA000191

11/6/17, 10:19 AM

ORIGIN ID:MMRA (661) 313-4735  
DEL BIGTREE  
INFORMED CONSENT ACTION NETWORK  
10200 US HWY 290 W. SUITE 301

AUSTIN, TX 78736  
UNITED STATES US

SHIP DATE: 06NOV17  
ACTWGT: 1.00 LB  
CAD: 111725408/NET3920

BILL SENDER

TO **ERIC HARGAN**  
**HHS OFFICE OF THE SECRETARY**  
**200 INDEPENDENCE AVE SW**

54933FB77104C

**WASHINGTON DC 20201**

(877) 696-6775

REF: HHS NOTICE FOLLOW UP

IN

SEPT



**FedEx**  
Express



1177110013136

TUE - 07 NOV 3:00P

STANDARD OVERNIGHT

TRK# 7706 7713 9900


0201

DSR

**XC WASA**

20201

DC-US IAD



## Polasky, Alexandra

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen  
**Cc:** Gruber, Marion; Finn, Theresa  
**Subject:** RE: Letter from ICAN re: vaccine safety  
**Attachments:** Pediatric vaccines.doc

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,  
Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Anderson, Steven <Steven.Anderson@fda.hhs.gov>  
**Cc:** Bartell, Diane <Diane.Bartell@fda.hhs.gov>; Gardner, Walter <Walter.Gardner@fda.hhs.gov>; Bell, Maureen <Maureen.Bell@fda.hhs.gov>; Raine, Kristine <Kristine.Raine@fda.hhs.gov>; Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V- CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie

**Sent:** Thursday, November 09, 2017 10:38 AM

**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>

**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>

**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## Pediatric vaccines

Your letter contains several inaccurate assertions. First, contrary to your assertion, many pediatric vaccines have been investigated in clinical trials that included inert placebo in place of the vaccine. Second, there appears to be a misunderstanding regarding the term "solicited" adverse events. Typically, in vaccine trials, the incidence of certain specific clinical findings that might be expected after vaccination is monitored for a short period of time after vaccination. Because these events are pre-specified, they are called "solicited" events. In addition to this, other unexpected or severe adverse events, which may occur a longer period of time after vaccination, are also analyzed and reviewed by FDA, but because these events are not predicted prior to initiation of the study, these are not called "solicited" adverse events. Third, vaccine safety is carefully examined regardless of whether or not there is an inert placebo group in the initial clinical trials. Once vaccines are approved, the safety is also carefully monitored, in some cases by manufacturer-conducted post-marketing studies, by VAERS, by VSD, by PRISM, and by other mechanisms.

1. Inert placebo controls are not required to understand the safety profile of a new vaccine, and are thus not required. In some cases, inclusion of inert placebo control groups can even be unethical. Control groups can be useful in evaluating whether or not the incidence of a specific observed adverse event exceeds that which would be expected without administration of the new vaccine, but do not provide the only way of doing so. Serious adverse events are always carefully reviewed to determine potential association with vaccination regardless of their rate of incidence in the control group. In cases where an active control is used, the adverse event profile of that control group is usually known and the findings of the study are reviewed in the context of that knowledge.
2. Data relied upon in licensing infant use of hepatitis B vaccines is summarized in the respective package inserts. This includes the safe use of these vaccines in individuals in older age groups. While not specifically reviewed in the context of initial licensure, pediatric data from other countries and in the literature also supported the safety of these vaccines in infants. The recommendation for all children to receive these vaccines was made by the Advisory Committee for Immunization Practices. Their reasoning is summarized in MMWR 1991. Follow-up studies have confirmed the safety of infant vaccination with hepatitis B vaccines (OBE study).

**Commented [KP1]:** Maybe worth taking a look at the SBAs from back then? They aren't on the web.

## Polasky, Alexandra

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 2:51 PM  
**To:** Krause, Philip; Gruber, Marion; Finn, Theresa  
**Subject:** RE: Letter from ICAN re: vaccine safety  
**Attachments:** Pediatric vaccines.doc

Thanks Phil. I made a few edits, to try to soften it. Appreciate Marion's and Theresa's review as well.

Maureen

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,  
Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Anderson, Steven <Steven.Anderson@fda.hhs.gov>  
**Cc:** Bartell, Diane <Diane.Bartell@fda.hhs.gov>; Gardner, Walter <Walter.Gardner@fda.hhs.gov>; Bell, Maureen <Maureen.Bell@fda.hhs.gov>; Raine, Kristine <Kristine.Raine@fda.hhs.gov>; Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V- CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie  
**Sent:** Thursday, November 09, 2017 10:38 AM  
**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>  
**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## II. Pre-Licensure Safety Review of Pediatric Vaccines

~~Your letter contains several inaccurate assertions~~ Thank you for the opportunity to correct the accuracies and misinformation conveyed in this section of your letter. First, ~~e~~Contrary to your ~~assertion~~ understanding, many pediatric vaccines have been investigated in clinical trials that included inert placebo in place of the vaccine. Second, ~~In addition~~, there appears to be a misunderstanding regarding the term “solicited” adverse events. Typically, in vaccine trials, the incidence of certain specific clinical findings that might be expected after vaccination is monitored for a short period of time after vaccination. Because these events are pre-specified, they are ~~called~~ considered to be “solicited” events. In addition to this, other unexpected or severe adverse events, which may occur a longer period of time ~~after~~ following vaccination, are also analyzed and reviewed by FDA, but because these events are not predicted prior to initiation of the study, these are not called “solicited” adverse events. ~~Third~~ Please be assured that, vaccine safety is carefully examined regardless of whether ~~or not~~ there is an inert placebo group in the initial clinical trials. Once vaccines are approved, the safety is also carefully monitored, in some cases by manufacturer-conducted post-marketing studies, by VAERS, by VSD, by PRISM, and by other mechanisms.

Responses below correspond to the specific questions posed in your letter:

1. Inert placebo controls are not required to understand the safety profile of a new vaccine, and are thus not required. In some cases, inclusion of inert placebo control groups ~~are~~ even be is considered unethical. Control groups can be useful in evaluating whether ~~or not~~ the incidence of a specific observed adverse event exceeds that which would be expected without administration of the new vaccine, but do not provide the only way of doing so. Serious adverse events are always carefully reviewed by FDA to determine potential association with vaccination regardless of their rate of incidence in the control group. In cases where an active control is used, the adverse event profile of that control group is usually known and the findings of the study are reviewed in the context of that knowledge.
2. Data relied upon in licensing infant use of hepatitis B vaccines is summarized in the respective package inserts. This includes the safe use of these vaccines in individuals in older age groups. While not specifically reviewed in the context of initial licensure, pediatric data from other countries and in the literature also supported the safety of these vaccines in infants. The recommendation for all children to receive these vaccines was made by the Advisory Committee for Immunization Practices. Their reasoning is summarized in MMWR 1991. Follow-up studies have confirmed support the safety of infant vaccination with hepatitis B vaccines. (OBE study).

**Commented [KP1]:** Maybe worth taking a look at the SBAs from back then? They aren't on the web.

## Polasky, Alexandra

---

**From:** Gruber, Marion  
**Sent:** Thursday, November 30, 2017 3:25 PM  
**To:** Hess, Maureen; Krause, Philip; Finn, Theresa  
**Subject:** RE: Letter from ICAN re: vaccine safety  
**Attachments:** Pediatric vaccines.doc

I am ok with the letter but do not think we get away with the first sentence, see suggestion.

Maureen, I will reach out to you tomorrow regarding a separate letter. Peter Marks had a meeting with OCOD Monday am to debate how to respond to a very inflammatory letter Lynn Redwood wrote him (thimerosal and vaccines). it was decided to keep the response short and high level, I am currently reviewing and think it is fine what OCOD wrote but I will run by you tomorrow before sending back to OCOD.

Marion

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 2:51 PM  
**To:** Krause, Philip <Philip.Krause@fda.hhs.gov>; Gruber, Marion <Marion.Grubert@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Thanks Phil. I made a few edits, to try to soften it. Appreciate Marion's and Theresa's review as well.

Maureen

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Grubert@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Grubert@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,

Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <[Lorrie.McNeill@fda.hhs.gov](mailto:Lorrie.McNeill@fda.hhs.gov)>; Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V- CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie  
**Sent:** Thursday, November 09, 2017 10:38 AM  
**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>  
**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## II. Pre-Licensure Safety Review of Pediatric Vaccines

~~Your letter contains several inaccurate assertions~~ Thank you for the opportunity to correct the accuracies and misinformation conveyed in this section of your letter. ~~First, e~~ Contrary to your assertion understanding, many pediatric vaccines have been investigated in clinical trials that included inert placebo in place of the vaccine. ~~Second, In addition,~~ there appears to be a misunderstanding regarding the term “solicited” adverse events. Typically, in vaccine trials, the incidence of certain specific clinical findings that might be expected after vaccination is monitored for a short period of time after vaccination. Because these events are pre-specified, they are ~~called~~ considered to be “solicited” events. In addition to this, other unexpected or severe adverse events, which may occur a longer period of time ~~after following~~ after vaccination, are also analyzed and reviewed by FDA, but because these events are not predicted prior to initiation of the study, these are not called “solicited” adverse events. ~~Third~~ Please be assured that, vaccine safety is carefully examined regardless of whether ~~or not~~ there is an inert placebo group in the initial clinical trials. Once vaccines are approved, the safety is also carefully monitored, in some cases by manufacturer-conducted post-marketing studies, by VAERS, by VSD, by PRISM, and by other mechanisms.

**Commented [GM1]:** While I love this sentence, I do not think we get away with it. For some reason, we always have to be polite. Consider: “Thank you for the opportunity to comment on some statements made in your letter.”

Responses below correspond to the specific questions posed in your letter:

1. Inert placebo controls are not required to understand the safety profile of a new vaccine, and are thus not required. In some cases, inclusion of inert placebo control groups ~~can even be is considered~~ unethical. Control groups can be useful in evaluating whether ~~or not~~ the incidence of a specific observed adverse event exceeds that which would be expected without administration of the new vaccine, but do not provide the only way of doing so. Serious adverse events are always carefully reviewed by FDA to determine potential association with vaccination regardless of their rate of incidence in the control group. In cases where an active control is used, the adverse event profile of that control group is usually known and the findings of the study are reviewed in the context of that knowledge.
2. Data relied upon in licensing infant use of hepatitis B vaccines is summarized in the respective package inserts. This includes the safe use of these vaccines in individuals in older age groups. While not specifically reviewed in the context of initial licensure, pediatric data from other countries and in the literature also supported the safety of these vaccines in infants. ~~The~~ re recommendation for all children to receive these vaccines was made by the Advisory Committee for Immunization Practices. Their reasoning is summarized in MMWR 1991. Follow-up studies ~~have confirmed support~~ have confirmed support the safety of infant vaccination with hepatitis B vaccines. ~~(OBE study).~~

**Commented [KP2]:** Maybe worth taking a look at the SBAs from back then? They aren't on the web.

## Polasky, Alexandra

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 4:04 PM  
**To:** Gruber, Marion; Krause, Philip; Finn, Theresa  
**Subject:** RE: Letter from ICAN re: vaccine safety  
**Attachments:** Pediatric vaccines.doc

Okay, here is another, softer version.

Maureen

---

**From:** Gruber, Marion  
**Sent:** Thursday, November 30, 2017 3:25 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

I am ok with the letter but do not think we get away with the first sentence, see suggestion.

Maureen, I will reach out to you tomorrow regarding a separate letter. Peter Marks had a meeting with OCOD Monday am to debate how to respond to a very inflammatory letter Lynn Redwood wrote him (thimerosal and vaccines). it was decided to keep the response short and high level, I am currently reviewing and think it is fine what OCOD wrote but I will run by you tomorrow before sending back to OCOD.

Marion

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 2:51 PM  
**To:** Krause, Philip <Philip.Krause@fda.hhs.gov>; Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Thanks Phil. I made a few edits, to try to soften it. Appreciate Marion's and Theresa's review as well.

Maureen

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>  
**Cc:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Cc:** Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,  
Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <[Lorrie.McNeill@fda.hhs.gov](mailto:Lorrie.McNeill@fda.hhs.gov)>; Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V- CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie  
**Sent:** Thursday, November 09, 2017 10:38 AM  
**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>  
**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by

HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## II. Pre-Licensure Safety Review of Pediatric Vaccines

~~Your letter contains several inaccurate assertions.~~ Thank you for the opportunity to address the concerns conveyed in this section of your letter. ~~First,~~ ~~Contrary to your assertions,~~ understanding, many pediatric vaccines have been investigated in clinical trials that included inert placebo in place of the vaccine. ~~Second,~~ In addition, there appears to be a misunderstanding regarding the term “solicited” adverse events. Typically, in vaccine trials, the incidence of certain specific clinical findings that might be expected after vaccination is monitored for a short period of time after vaccination. Because these events are pre-specified, they are ~~called~~ considered to be “solicited” events. In addition to this, other unexpected or severe adverse events, which may occur a longer period of time ~~after~~ following vaccination, are also analyzed and reviewed by FDA, but because these events are not predicted prior to initiation of the study, these are not called “solicited” adverse events. ~~Third,~~ Please be assured that ~~—~~ vaccine safety is carefully examined regardless of whether ~~or not~~ there is an inert placebo group in the initial clinical trials. Once vaccines are approved, the safety is also carefully monitored, in some cases by manufacturer-conducted post-marketing studies, by VAERS, by VSD, by PRISM, and by other mechanisms.

Responses below correspond to the specific questions posed in your letter:

1. Inert placebo controls are not required to understand the safety profile of a new vaccine, and are thus not required. In some cases, inclusion of inert placebo control groups ~~can~~ even be is considered unethical. Control groups can be useful in evaluating whether ~~or not~~ the incidence of a specific observed adverse event exceeds that which would be expected without administration of the new vaccine, but do not provide the only way of doing so. Serious adverse events are always carefully reviewed by FDA to determine potential association with vaccination regardless of their rate of incidence in the control group. In cases where an active control is used, the adverse event profile of that control group is usually known and the findings of the study are reviewed in the context of that knowledge.
2. Data relied upon in licensing infant use of hepatitis B vaccines is summarized in the respective package inserts. This includes the safe use of these vaccines in individuals in older age groups. While not specifically reviewed in the context of initial licensure, pediatric data from other countries and in the literature also supported the safety of these vaccines in infants. The recommendation for all children to receive these vaccines was made by the Advisory Committee for Immunization Practices. Their reasoning is summarized in MMWR 1991. Follow-up studies have confirmed support the safety of infant vaccination with hepatitis B vaccines. ~~(OBE study).~~

**Commented [KP1]:** Maybe worth taking a look at the SBAs from back then? They aren't on the web.

## Polasky, Alexandra

---

**From:** Hess, Maureen  
**Sent:** Friday, December 1, 2017 4:41 PM  
**To:** Finn, Theresa  
**Cc:** Krause, Philip; Gruber, Marion  
**Subject:** RE: Letter from ICAN re: vaccine safety

Theresa,

Do you want to take a look too, (next week is fine) in case you have something to add?

Maureen

---

**From:** Gruber, Marion  
**Sent:** Thursday, November 30, 2017 4:09 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

This looks good to me.

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 4:04 PM  
**To:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Okay, here is another, softer version.

Maureen

---

**From:** Gruber, Marion  
**Sent:** Thursday, November 30, 2017 3:25 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

I am ok with the letter but do not think we get away with the first sentence, see suggestion.

Maureen, I will reach out to you tomorrow regarding a separate letter. Peter Marks had a meeting with OCOD Monday am to debate how to respond to a very inflammatory letter Lynn Redwood wrote him (thimerosal and vaccines). it was decided to keep the response short and high level, I am currently reviewing and think it is fine what OCOD wrote but I will run by you tomorrow before sending back to OCOD.

Marion

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 2:51 PM  
**To:** Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Thanks Phil. I made a few edits, to try to soften it. Appreciate Marion's and Theresa's review as well.

Maureen

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Cc:** Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,  
Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <[Lorrie.McNeill@fda.hhs.gov](mailto:Lorrie.McNeill@fda.hhs.gov)>; Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V-

CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie

**Sent:** Thursday, November 09, 2017 10:38 AM

**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>

**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>

**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## Polasky, Alexandra

---

**From:** Krause, Philip  
**Sent:** Friday, December 8, 2017 3:09 PM  
**To:** Finn, Theresa; Hess, Maureen; Gruber, Marion  
**Subject:** RE: Letter from ICAN re: vaccine safety  
**Attachments:** Pediatric vaccines.doc

Looks good to me. I added the hep B MMWR reference.

---

**From:** Finn, Theresa  
**Sent:** Thursday, December 07, 2017 5:32 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>; Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

Maureen and I worked on this a bit more. Please take a look and make sure you are OK with it.

Theresa

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 4:04 PM  
**To:** Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Okay, here is another, softer version.

Maureen

---

**From:** Gruber, Marion  
**Sent:** Thursday, November 30, 2017 3:25 PM  
**To:** Hess, Maureen <Maureen.Hess@fda.hhs.gov>; Krause, Philip <Philip.Krause@fda.hhs.gov>; Finn, Theresa <Theresa.Finn@fda.hhs.gov>  
**Subject:** RE: Letter from ICAN re: vaccine safety

I am ok with the letter but do not think we get away with the first sentence, see suggestion.

Maureen, I will reach out to you tomorrow regarding a separate letter. Peter Marks had a meeting with OCOD Monday am to debate how to respond to a very inflammatory letter Lynn Redwood wrote him (thimerosal and vaccines). it was decided to keep the response short and high level, I am currently reviewing and think it is fine what OCOD wrote but I will run by you tomorrow before sending back to OCOD.

Marion

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 30, 2017 2:51 PM  
**To:** Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Thanks Phil. I made a few edits, to try to soften it. Appreciate Marion's and Theresa's review as well.

Maureen

---

**From:** Krause, Philip  
**Sent:** Thursday, November 30, 2017 12:33 PM  
**To:** Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Hi Maureen, here are a few ideas, thanks! Phil

---

**From:** Hess, Maureen  
**Sent:** Friday, November 24, 2017 4:50 PM  
**To:** Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Cc:** Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Finn, Theresa <[Theresa.Finn@fda.hhs.gov](mailto:Theresa.Finn@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Phil,

When this correspondence came in, we discussed it briefly in Marion's office. You said that you had some ideas on how we should answer II, "Deficiencies in the Pre-licensure Safety Review of Pediatric Vaccines." Can you put something together?

Thanks,  
Maureen

---

**From:** Hess, Maureen  
**Sent:** Thursday, November 09, 2017 4:19 PM  
**To:** McNeill, Lorrie <[Lorrie.McNeill@fda.hhs.gov](mailto:Lorrie.McNeill@fda.hhs.gov)>; Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Krause, Philip <[Philip.Krause@fda.hhs.gov](mailto:Philip.Krause@fda.hhs.gov)>  
**Subject:** RE: Letter from ICAN re: vaccine safety

Lorrie,

This is the same guy that just wrote us about Gardasil, which we are also working on a response. I saw this yesterday and wondered to myself how this could be FYI. You are correct in that not all of his concerns are in FDA's lane. I think that your suggestion of NVPO coordinating is spot on. We've gone through it and I can tell you what we can answer and who we suggest for certain

sections. Roman numeral II is us, III- OBE, IV- CDC, though OBE may have info to contribute, V- CDC, but Phil recalls OBE doing some genomics studies on this subject, so they may have some language, VII- NVPO, VIII- HHS, CDC, but CBER ACS will need to provide language to respond to his issue regarding VRBPAC.

What is the deadline for responding to this?

Maureen

---

**From:** McNeill, Lorrie  
**Sent:** Thursday, November 09, 2017 10:38 AM  
**To:** Anderson, Steven <[Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov)>; Gruber, Marion <[Marion.Gruber@fda.hhs.gov](mailto:Marion.Gruber@fda.hhs.gov)>; Hess, Maureen <[Maureen.Hess@fda.hhs.gov](mailto:Maureen.Hess@fda.hhs.gov)>  
**Cc:** Bartell, Diane <[Diane.Bartell@fda.hhs.gov](mailto:Diane.Bartell@fda.hhs.gov)>; Gardner, Walter <[Walter.Gardner@fda.hhs.gov](mailto:Walter.Gardner@fda.hhs.gov)>; Bell, Maureen <[Maureen.Bell@fda.hhs.gov](mailto:Maureen.Bell@fda.hhs.gov)>; Raine, Kristine <[Kristine.Raine@fda.hhs.gov](mailto:Kristine.Raine@fda.hhs.gov)>  
**Subject:** Letter from ICAN re: vaccine safety

Good morning all – we received the attached correspondence as an FYI and had shared with Maureen, but it has now been sent to us by FDA Exec Sec as a direct reply. In reading through, it's my opinion that this should be coordinated by HHS or NVPO, as the questions being asked need input from multiple agencies. We can push back and make this suggestion – that we only be responsible for providing language for those questions that pertain to FDA.

Can you let us know if you agree with this approach, or if you have any other suggestions on how best to proceed?

Thanks in advance –

Lorrie

## II. Pre-Licensure Safety Review of Pediatric Vaccines

~~Your letter contains several inaccurate assertions~~ Thank you for the opportunity to address the concerns conveyed in this section of your letter. ~~First, contrary to your assertion understanding,~~ many pediatric vaccines have been investigated in clinical trials that included ~~inert~~ a placebo in place of the vaccine. ~~Second, in addition,~~ there appears to be a misunderstanding regarding the term “solicited” adverse events. Typically, in vaccine trials, the incidence of certain specific clinical findings that might be expected after vaccination is monitored for a short period of time after vaccination. Because these events are pre-specified, they are ~~called~~ considered to be “solicited” events. In addition to this, other unexpected or severe adverse events, which may occur a longer period of time ~~after~~ following vaccination, are also analyzed and reviewed by FDA, but because these events are not predicted prior to initiation of the study, these are not called “solicited” adverse events. ~~Third, please be assured that,~~ vaccine safety is carefully examined regardless of whether ~~or not~~ there is ~~an inert~~ a placebo group included in the initial clinical trials. Once vaccines are approved, the safety is also carefully monitored, in some cases by manufacturer-conducted post-marketing studies, by VAERS, by VSD, by PRISM, and by other mechanisms.

The ~~r~~Responses below correspond to the specific questions posed in your letter:

1. Inert placebo controls are not required to understand the safety profile of a new vaccine, and are thus not required. In some cases, inclusion of ~~inert~~ placebo control groups ~~can even be is considered unethical.~~ Even in the absence of a placebo, ~~c~~Control groups ~~can~~ groups can be useful in evaluating whether ~~or not~~ the incidence of a specific observed adverse event exceeds that which would be expected without administration of the new vaccine, but do not provide the only way of doing so. Serious adverse events are always carefully ~~reviewed~~ evaluated by FDA to determine potential association with vaccination regardless of their rate of incidence in the control group. In cases where an active control is used, the adverse event profile of that control group is usually known and the findings of the study are reviewed in the context of that knowledge.
2. Data relied upon in licensing infant use of hepatitis B vaccines is summarized in the respective package inserts. ~~This includes the safe use of these vaccines in individuals in older age groups. While not specifically reviewed in the context of initial licensure~~ Furthermore, pediatric data from other countries and in the literature also supported the safety of these vaccines in infants. ~~The~~ recommendation for all children to receive these vaccines was made by the Advisory Committee for Immunization Practices. Their reasoning is summarized in MMWR 1991 (<https://www.cdc.gov/mmwr/preview/mmwrhtml/00033405.htm>). Follow-up studies have ~~confirmed~~ support the safety of infant vaccination with hepatitis B vaccines. ~~(OBE study).~~

Commented [KP1]: Maybe worth taking a look at the SBAs from back then? They aren't on the web.